Nan Fung Trinity (Hk) LTD Trevi Therapeutics, Inc. Transaction History
Nan Fung Trinity (Hk) LTD
- $910 Million
- Q3 2025
A detailed history of Nan Fung Trinity (Hk) LTD transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Nan Fung Trinity (Hk) LTD holds 89,575 shares of TRVI stock, worth $966,514. This represents 0.09% of its overall portfolio holdings.
Number of Shares
89,575Holding current value
$966,514% of portfolio
0.09%Shares
1 transactions
Others Institutions Holding TRVI
# of Institutions
170Shares Held
111MCall Options Held
1.07MPut Options Held
425K-
Nea Management Company, LLC Timonium, MD13.2MShares$143 Million6.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$111 Million2.96% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$92.1 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.32MShares$57.4 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.49MShares$48.4 Million5.2% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $629M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...